SCHEMBL4850801

SCHEMBL4850801

O=c1oc(-c2ccccc2)nc2cc(F)c(F)cc12

nearest known ligand 0.66

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ELANE P08246 2/20 0.66
HPN P05981 1/20 0.58
NPC1 O15118 5/20 0.54
RAB9A P51151 4/20 0.54
C1R P00736 3/20 0.54
RXFP1 Q9HBX9 1/20 0.54
KMT2A Q03164 3/20 0.52
MEN1 O00255 2/20 0.52
F2 P00734 2/20 0.51
ALDH1A1 P00352 6/20 0.50
MAPT P10636 5/20 0.50
KDM4E B2RXH2 3/20 0.50
HPGD P15428 3/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
LMNA P02545 2/20 0.50
APEX1 P27695 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.49
TP53 P04637 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10780103 0.89 ELANE (0.77) ELANEHPNNPC1RAB9AC1R
SCHEMBL10781834 0.87 ELANE (0.74) ELANEHPNNPC1RAB9AC1R
SCHEMBL9744461 0.83 ELANE (0.69) ELANEHPNNPC1RAB9AC1R
SCHEMBL915773 0.83 C1R (0.73) ELANEC1RKMT2AMEN1F2
SCHEMBL913631 0.81 F7 (0.67) ELANEHPNC1RKMT2AMEN1
SCHEMBL692804 0.80 ELANE (0.64) ELANEHPNNPC1RAB9ARXFP1
SCHEMBL692236 0.80 HPN (0.76) ELANEHPNNPC1RAB9ARXFP1
SCHEMBL272702 0.80 ELANE (1.00) ELANENPC1RAB9AC1RRXFP1
SCHEMBL29382161 0.80 ELANE (1.00) ELANENPC1RAB9AC1RRXFP1
SCHEMBL12927384 0.79 C1R (0.66) ELANENPC1RAB9AC1RRXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7326788-B2 Selective, potent small molecule protein tyrosine kinase inhibitors; such as 6-chloro-3-(3-methyl-isoxazol-5-yl)-4-(pyridin-4-yl)-1H-quinolin-2-one JANSSEN PHARMACEUTICA N.V. (BE) 2008-02-05 US disclosed
EP-1660087-A2 QUINOLINONE DERIVATIVES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-31 EP disclosed
US-20050049274-A1 Quinolinone derivatives as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2005-03-03 US disclosed
WO-2005009967-A2 QUINOLINONE DERIVATIVES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2005-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049274-A1 Quinolinone derivatives as inhibitors of c-fms kinase FLT3, ABL1, FES ELANE 4351/4885HPN 3807/4885NPC1 4399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.